Investor Briefcase   
Investor Kit   
News Feeds    
Print page    Print
E-mail page    E-mail





 


PRESS RELEASES

= Add Release to Briefcase
All Releases
View Summary FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
06-16-09
PDF 11.3 KB Add to Briefcase
View Summary Savient Announces Election of Dr. Ginger D. Constantine to Board of Directors
06-05-09
PDF 9.2 KB Add to Briefcase
View Summary Savient to Present Multiple Abstracts At the European League Against Rheumatism (EULAR) 2009 Annual Congress
05-29-09
PDF 13.7 KB Add to Briefcase
View Summary Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
05-07-09
PDF 11.0 KB Add to Briefcase
View Summary Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
05-06-09
PDF 16.8 KB Add to Briefcase
View Summary Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
05-05-09
PDF 11.5 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 14, 2009
05-01-09
PDF 8.9 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Hold First Quarter 2009 Financial Results Conference Call On Thursday, May 7, 2009
04-24-09
PDF 9.1 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
04-03-09
PDF 10.8 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
03-09-09
PDF 8.1 KB Add to Briefcase
View Summary Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
02-25-09
PDF 18.5 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
02-17-09
PDF 8.4 KB Add to Briefcase
View Summary Savient Announces Appointment of David Gionco as Chief Financial Officer
02-12-09
PDF 11.2 KB Add to Briefcase
View Summary Savient Provides Update on Pegloticase BLA
02-12-09
PDF 18.4 KB Add to Briefcase
View Summary Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
01-28-09
PDF 10.8 KB Add to Briefcase
View Summary Pegloticase BLA Filing Accepted for Priority Review by FDA
12-29-08
PDF 11.6 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
12-08-08
PDF 8.2 KB Add to Briefcase
View Summary Savient's Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
11-19-08
PDF 15.8 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
11-13-08
PDF 8.8 KB Add to Briefcase
View Summary Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
11-06-08
PDF 8.8 KB Add to Briefcase
Showing 1-20 of 66 releases Page: 1 2 3 4  See Next 20

 

Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.

     
CONTACT US    |    PRIVACY    |    TERMS OF USE
Copyright © 2009 Savient Pharmaceuticals, Inc. All rights reserved.